©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2013; 19(30): 4877-4886
Published online Aug 14, 2013. doi: 10.3748/wjg.v19.i30.4877
Published online Aug 14, 2013. doi: 10.3748/wjg.v19.i30.4877
Table 3 Treatments n (%)
| Thiopurines (n = 429) | No thiopurines (n = 383) | P value | |
| TPMT activity | 283 (66) | - | |
| Low | 5 (1.8) | - | |
| Intermediate | 43 (15.2) | - | |
| High | 235 (83) | - | |
| Azathioprine | 341 (79.5) | - | |
| Mercaptopurine | 60 (14) | - | |
| Azathioprine + Mercaptopurine | 28 (6.5) | - | |
| Infliximab | 112 (26.1) | 7 (1.8) | < 0.001 |
| Adalimub | 50 (11.7) | 3 (0.8) | < 0.001 |
| Other immunosuppressants | 29 (6.8) | 4 (1) | < 0.001 |
- Citation: Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, Teresa-Galván JD, Redondo-Cerezo E. Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain. World J Gastroenterol 2013; 19(30): 4877-4886
- URL: https://www.wjgnet.com/1007-9327/full/v19/i30/4877.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i30.4877